Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Get insights on Alembic Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Alembic Pharmaceuticals Ltd Share Price Chart
Alembic Pharmaceuticals Ltd Fundamentals
Traded Volume: 68,194
Market Cap(Cr): 18,004
Avg Traded Price 585.69
1 Year return -11.44%
Upper Circuit 930
Lower Circuit 911
P/E TTM 28.00
P/B Ratio 32.00
Traded Value(Cr) 624.62
EPS TTM 32.275
Book value 32.275
Dividend 1.00%
Alembic Pharmaceuticals Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Alembic Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Alembic Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +0.07%
1M -2.94%
3M -3.33%
1Y -11.44%
YTD -12.62%
Alembic Pharmaceuticals Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Alembic Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 58952.00
Day Before Yesterday 38427.00
1W Avg 1.27L
1M Avg 1.55L
3M Avg 1.20L
Alembic Pharmaceuticals Ltd Technical Details
Alembic Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 911
Support 2 904
Support 3 897
Pivot Point : 918
Resistance 1 924
Resistance 2 932
Resistance 3 938
Alembic Pharmaceuticals Ltd Corporate Actions
Alembic Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Alembic Pharmaceuticals Ltd’s capital allocation strategies.
All
Ex-Date 29-Jul-2025 Type D Description 11.00/share@550.00% Record Date 29-Jul-2025 Ratio 550.00
Ex-Date 15-Jul-2024 Type D Description 11.00/share@550.00% Record Date 15-Jul-2024 Ratio 550.00
Ex-Date 28-Jul-2023 Type D Description 8.00/share@400.00% Record Date 28-Jul-2023 Ratio 400.00
Ex-Date 17-Aug-2022 Type D Description 10.00/share@500.00% Record Date 18-Aug-2022 Ratio 500.00
Ex-Date 19-Jul-2021 Type D Description 14.00/share@700.00% Record Date 13-Nov-2025 Ratio 700.00
Ex-Date 16-Mar-2020 Type D Description 7.00/share@350.00% Record Date 17-Mar-2020 Ratio 350.00
Ex-Date 16-Mar-2020 Type D Description 3.00/share@150.00% Record Date 17-Mar-2020 Ratio 150.00
Ex-Date 18-Jul-2019 Type D Description 5.50/share@275.00% Record Date 13-Nov-2025 Ratio 275.00
Ex-Date 18-Jul-2018 Type D Description 4.00/share@200.00% Record Date 13-Nov-2025 Ratio 200.00
Ex-Date 11-Jul-2017 Type D Description 4.00/share@200.00% Record Date 13-Nov-2025 Ratio 200.00
Ex-Date 20-Jul-2016 Type D Description 4.00/share@200.00% Record Date 13-Nov-2025 Ratio 200.00
Ex-Date 22-Jul-2015 Type D Description 3.50/share@175.00% Record Date 13-Nov-2025 Ratio 175.00
Ex-Date 17-Jul-2014 Type D Description 3.00/share@150.00% Record Date 13-Nov-2025 Ratio 150.00
Ex-Date 29-Jul-2013 Type D Description 2.50/share@125.00% Record Date 13-Nov-2025 Ratio 125.00
Ex-Date 31-Jul-2012 Type D Description 1.40/share@70.00% Record Date 13-Nov-2025 Ratio 70.00
Dividends
Announcement Date 29-Jul-2025 Ex Dividend Date 29-Jul-2025 Dividend(%) 550
Announcement Date 15-Jul-2024 Ex Dividend Date 15-Jul-2024 Dividend(%) 550
Announcement Date 28-Jul-2023 Ex Dividend Date 28-Jul-2023 Dividend(%) 400
Announcement Date 17-Aug-2022 Ex Dividend Date 17-Aug-2022 Dividend(%) 500
Announcement Date 19-Jul-2021 Ex Dividend Date 19-Jul-2021 Dividend(%) 700
Announcement Date 16-Mar-2020 Ex Dividend Date 16-Mar-2020 Dividend(%) 350
Announcement Date 16-Mar-2020 Ex Dividend Date 16-Mar-2020 Dividend(%) 150
Announcement Date 18-Jul-2019 Ex Dividend Date 18-Jul-2019 Dividend(%) 275
Announcement Date 18-Jul-2018 Ex Dividend Date 18-Jul-2018 Dividend(%) 200
Announcement Date 11-Jul-2017 Ex Dividend Date 11-Jul-2017 Dividend(%) 200
Announcement Date 20-Jul-2016 Ex Dividend Date 20-Jul-2016 Dividend(%) 200
Announcement Date 22-Jul-2015 Ex Dividend Date 22-Jul-2015 Dividend(%) 175
Announcement Date 17-Jul-2014 Ex Dividend Date 17-Jul-2014 Dividend(%) 150
Announcement Date 29-Jul-2013 Ex Dividend Date 29-Jul-2013 Dividend(%) 125
Announcement Date 31-Jul-2012 Ex Dividend Date 31-Jul-2012 Dividend(%) 70
Bonus
No Bonus has been declared by APLLTD
Splits
No Split has been declared by APLLTD
Others
Rights No Rights has been declared by APLLTD
Alembic Pharmaceuticals Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Alembic Pharmaceuticals Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Alembic Pharmaceuticals Ltd's relative performance and valuation against major competitors.
Stock Name ERIS Lifesciences Ltd ₹1518.10 (-3.62%) M. Cap (Cr) 206.79 1 Yr Return (%) +10.85% P/E (TTM) 50.40 PB Ratio 7.56
Stock Name OneSource Specialty Pharma Ltd ₹1726.00 (-1.81%) M. Cap (Cr) 197.67 1 Yr Return (%) NaN% P/E (TTM) 494.77 PB Ratio 3.36
Stock Name Sai Life Sciences Ltd ₹870.70 (-2.21%) M. Cap (Cr) 183.00 1 Yr Return (%) NaN% P/E (TTM) 63.89 PB Ratio 18.91
Stock Name Alembic Pharmaceuticals Ltd ₹915.95 (-0.08%) M. Cap (Cr) 180.04 1 Yr Return (%) -11.44% P/E (TTM) 28.38 PB Ratio 3.47
Stock Name Jubilant Pharmova Ltd ₹1126.00 (-1.21%) M. Cap (Cr) 179.37 1 Yr Return (%) -5.40% P/E (TTM) 37.54 PB Ratio 3.02
Stock Name Caplin Point Laboratories Ltd ₹1936.40 (-0.50%) M. Cap (Cr) 147.19 1 Yr Return (%) -3.70% P/E (TTM) 25.00 PB Ratio 5.79
Stock Name Natco Pharma Ltd ₹826.15 (+0.46%) M. Cap (Cr) 147.97 1 Yr Return (%) -40.60% P/E (TTM) 8.72 PB Ratio 1.95
Alembic Pharmaceuticals Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Alembic Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 226.57 Mar 2024 772.77 Mar 2023 730.25 Mar 2022 545.26 Mar 2021 1485.30
PARTICULARS Investing Activities Mar 2025 -636.08 Mar 2024 -329.02 Mar 2023 -460.98 Mar 2022 -368.72 Mar 2021 -925.55
PARTICULARS Financing Activities Mar 2025 403.61 Mar 2024 -445.29 Mar 2023 -261.16 Mar 2022 -216.64 Mar 2021 -533.60
PARTICULARS Net Cash Flow Mar 2025 -5.90 Mar 2024 -1.54 Mar 2023 8.11 Mar 2022 -40.10 Mar 2021 25.22
Alembic Pharmaceuticals Ltd Shareholding Pattern
This shows the ownership breakdown of Alembic Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 69.74%
Public 9.92%
Other Institutions 7.75%
FII 4.04%
Mutual Funds 8.55%
About Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.'.During 2015, the company's associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day-1. Also during the year, the company transitioned to own marketing in the US.In 2016, the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.In July 2017, Alembic Pharmaceuticals inaugurated a state of the art anti-cancer manufacturing facility at Panelav, Halol, Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US, Middle East, North Africa, Australia and South Africa. On 1 November 2017, Alembic Pharmaceuticals announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a state-of-the-art 8,600 square feet R&D and pilot manufacturing facility, Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs, Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at the company's formulation facility located at Panelav, Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations, which will be submitted to the US FDA shortly. On 24 April 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s.In 2019, the Company launched 9 new products in the US.In 2021, Rhizen's out-licenced, novel molecule Umbralicib (UKONIQ) was launched by TG Therapeutics USA. During the year 2021-22, the Company acquired the balance 40% stake held by the joint venture partner in Aleor DermaceuticalsLimited (Aleor) and pursuant to said acquisition, Aleor became a wholly owned subsidiary of the Company.The wholly owned subsidiary, Aleor Dermaceuticals Limited got amalgamated with the Company, making the Scheme of Arrangement effective from 29th August, 2022.During FY23, the Company filed 20 ANDAs and received approvals for 22 ANDAs taking the total filed ANDAs to 245 as on March 31, 2023. At Panelav, Alembic set up dedicated blocks (F2) for manufacturing oncology products which was approved by the US FDA in 2022. The Company launched various new products, especially in the gynecology and anti-diabetic spaces; it launched 33 new SKUs in FY23, of which 66% were in specialty therapies. It established a subsidiary in Chile to gain a strong foothold in the large and growing Latin American markets. It opened a scientific office in the UAE to capitalise on the opportunities emerging from the GCC nations. Alembic launched 27 new products, including 18 oncology, derma and ophthalmic product in FY24. The Company launched products in speciality and animal health space in FY24. It formed a subsidiary in the UAE by setting up a scientific office during the year.The US Generic business scaled volumes to counter price erosion via strengthening the supply chain in FY 25. It has launched 16 new products, of which 9 OSD, 2 Injectable, 2 Ophthalmic, 3 Dermatology.
Chairman & CEO
Chirayu R Amin
Registered office Alembic Road, null, Vadodara, Gujarat, 390003
FAX :91-0265-2280550
Background
Incorporation Year 2010
Face Value ₹2.00
Market Lot 1
FAQs on Alembic Pharmaceuticals Ltd
How to buy Alembic Pharmaceuticals Ltd shares on NSE?
To buy Alembic Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Alembic Pharmaceuticals Ltd share price today?
The Alembic Pharmaceuticals Ltd share price on NSE is ₹915.95 today.
What is the market cap of Alembic Pharmaceuticals Ltd on NSE?
The company has a market capitalization of ₹18004.20.
What is the PE & PB ratio of Alembic Pharmaceuticals Ltd?
PE is 28 and PB is 32.
What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd shares?
Alembic Pharmaceuticals Ltd stock price high: ₹1123.95 Alembic Pharmaceuticals Ltd stock price low: ₹725.20.
How can I purchase stock in Alembic Pharma?
You can use the services of a reliable broker like Motilal Oswal to purchase stock in Alembic Pharma. All you have to do is sign up with the broker and open demat and trading accounts. You can buy stocks in Alembic Pharma on the stock exchange through the broker.
Is Alembic Pharma a good investment?
According to some analysts, Alembic Pharma is an undervalued stock at present. Still, it may be a good investment if you are thinking of a long-term view as the stock may see an upside in the future.
Is Alembic Pharma debt-free?
In September 2022, Alembic Pharma held debt at approximately Rs. 7.71 billion, down from the previous year.
What is the dividend yield of Alembic Pharma?
The dividend yield of Alembic Pharma is 2.09% (March 2022).